Palliative treatment of malignant ascites: profile of catumaxomab

Lila Ammouri, Eric E PrommerMayo Clinic Hospice and Palliative Medicine Program, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Scottsdale, AZ, USAAbstract: Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity associated with several intrapelvic and intra-abdomina...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lila Ammouri, Eric E Prommer
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/14ed5f20d4c94c798e4322c6cf20a339
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:14ed5f20d4c94c798e4322c6cf20a339
record_format	dspace
spelling	oai:doaj.org-article:14ed5f20d4c94c798e4322c6cf20a3392021-12-02T08:15:15ZPalliative treatment of malignant ascites: profile of catumaxomab1177-54751177-5491https://doaj.org/article/14ed5f20d4c94c798e4322c6cf20a3392010-05-01T00:00:00Zhttp://www.dovepress.com/palliative-treatment-of-malignant-ascites-profile-of-catumaxomab-a4439https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Lila Ammouri, Eric E PrommerMayo Clinic Hospice and Palliative Medicine Program, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Scottsdale, AZ, USAAbstract: Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity associated with several intrapelvic and intra-abdominal malignancies. The development of ascites leads to significant symptoms and poor quality of life for the cancer patient. Available therapies for palliation include treatment of the underlying disease, but when there are no treatment options, the use of diuretics, implantation of drainage catheters, and surgical shunting techniques are considered. None of these symptom palliation options affect the course of disease. The development of trifunctional antibodies, which attach to specific overexpressed surface markers on tumor cells, and trigger an immune response leading to cytoreductive effects, represents a new approach to the management of malignant ascites. The purpose of this review is to highlight current therapies for malignant ascites and review data as to the effectiveness of a new trifunctional antibody, catumaxomab.Keywords: catumaxomab, ascites, trifunctional Lila AmmouriEric E PrommerDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 103-110 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Lila Ammouri Eric E Prommer Palliative treatment of malignant ascites: profile of catumaxomab
description	Lila Ammouri, Eric E PrommerMayo Clinic Hospice and Palliative Medicine Program, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Scottsdale, AZ, USAAbstract: Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity associated with several intrapelvic and intra-abdominal malignancies. The development of ascites leads to significant symptoms and poor quality of life for the cancer patient. Available therapies for palliation include treatment of the underlying disease, but when there are no treatment options, the use of diuretics, implantation of drainage catheters, and surgical shunting techniques are considered. None of these symptom palliation options affect the course of disease. The development of trifunctional antibodies, which attach to specific overexpressed surface markers on tumor cells, and trigger an immune response leading to cytoreductive effects, represents a new approach to the management of malignant ascites. The purpose of this review is to highlight current therapies for malignant ascites and review data as to the effectiveness of a new trifunctional antibody, catumaxomab.Keywords: catumaxomab, ascites, trifunctional
format	article
author	Lila Ammouri Eric E Prommer
author_facet	Lila Ammouri Eric E Prommer
author_sort	Lila Ammouri
title	Palliative treatment of malignant ascites: profile of catumaxomab
title_short	Palliative treatment of malignant ascites: profile of catumaxomab
title_full	Palliative treatment of malignant ascites: profile of catumaxomab
title_fullStr	Palliative treatment of malignant ascites: profile of catumaxomab
title_full_unstemmed	Palliative treatment of malignant ascites: profile of catumaxomab
title_sort	palliative treatment of malignant ascites: profile of catumaxomab
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/14ed5f20d4c94c798e4322c6cf20a339
work_keys_str_mv	AT lilaammouri palliativetreatmentofmalignantascitesprofileofcatumaxomab AT ericeprommer palliativetreatmentofmalignantascitesprofileofcatumaxomab
_version_	1718398586415218688

Palliative treatment of malignant ascites: profile of catumaxomab

Ejemplares similares